References
- Atkinson K, Vos B, Kang-Er Z, et al (1995).Effect of in vivo administration of IL-3 and IL-6, alone and in combination with G-CSF, GM-CSF or IL-1, on haematopoiesis, graftversus- host disease and survival after murine haematopoietic stem cell transplantation. Cytokines Mol Ther, 1, 47-55.
- Brickey WJ, Neuringer IP, Walton W, et al (2012).MyD88 provides a protective role in long-term radiation-induced lung injury. Int J Radiat Biol, 88, 335-47. https://doi.org/10.3109/09553002.2012.652723
- Burdelya LG, Gleiberman AS, Toshkov I, et al (2012). Tolllike receptor 5 agonist protects mice from dermatitis and oral mucositis caused by local radiation: implications for head-and-neck cancer radiotherapy. Int J Radiat Oncol Biol Phys, 83, 228-34. https://doi.org/10.1016/j.ijrobp.2011.05.055
- Burdelya LG, Krivokrysenko VI, Tallant TC, et al (2008). An agonist of toll-like receptor 5 has radioprotective activity in mouse and primate models. Science, 320, 226-30. https://doi.org/10.1126/science.1154986
- Dale DC (2002). Colony-stimulating factors for the management of neutropenia in cancer patients. Drugs, 62, S1-15.
- Delanian S, Baillet F, Huart J, et al (1994). Successful treatment of radiation-induced fibrosis using liposomal Cu/Zn superoxide dismutase (clinical trial). Radiother Oncol, 32, 12-20. https://doi.org/10.1016/0167-8140(94)90444-8
- Epperly MW, Sikora CA, DeFilippi SJ, et al (2002).Manganese superoxide dismutase (SOD2) inhibits radiation-induced apoptosis by stabilization of the mitochondrial membrane. Radiat Res, 157, 568-77. https://doi.org/10.1667/0033-7587(2002)157[0568:MSDSIR]2.0.CO;2
- Krivokrysenko V, Shakhov A, Singh V, et al (2012). Identification of G-CSF and IL-6 as Candidate Biomarkers of CBLB502 Efficacy as a Medical Radiation Countermeasure. J Pharmacol Exp Ther, 343, 497-508. https://doi.org/10.1124/jpet.112.196071
- Kuwano K, Hagimoto N, Kawasaki M, et al (1999). Essential roles of the Fas-Fas ligand pathway in the development of pulmonary fibrosis. J ClinInvest, 104, 13-9
- Mehta V (2005). Radiation pneumonitis and pulmonary fibrosis in non-small-cell lung cancer: pulmonary function, prediction, and prevention. Int J Radiat Oncol Biol Phys, 63, 5-24. https://doi.org/10.1016/j.ijrobp.2005.03.047
- Tallant T, Deb A, Kar N, et al (2004). Flagellin acting via TLR5 is the major activator of key signaling pathways leading to NF-kappa B and proinflammatory gene program activation in intestinal epithelial cells. BMCMicrobiol, 4, 33.
- Vijay-Kumar M, Aitken JD, Sanders CJ, et al (2008).Flagellin treatment protects against chemicals, bacteria,viruses, and radiation. J Immunol, 180, 8280-5. https://doi.org/10.4049/jimmunol.180.12.8280
- Wynn TA (2007). Common and unique mechanisms regulate fibrosis in various fibroproliferative diseases. J Clin Invest, 117, 524-9. https://doi.org/10.1172/JCI31487
- Zhou SX, Li FS, Qiao YL, et al (2012). Toll-like receptor 5 agonist inhibition of growth of A549 lung cancer cells in vivo in a Myd88 dependent manner. Asian Pac J Cancer Prev, 13, 2807-12. https://doi.org/10.7314/APJCP.2012.13.6.2807
Cited by
- Peptidoglycans Promotes Human Leukemic THP-1 Cell Apoptosis and Differentiation vol.13, pp.12, 2012, https://doi.org/10.7314/APJCP.2012.13.12.6409
- Suggestion for a New Grading Scale for Radiation Induced Pneumonitis Based on Radiological Findings of Computerized Tomography: Correlation with Clinical and Radiotherapeutic Parameters in Lung Cancer Patients vol.14, pp.5, 2013, https://doi.org/10.7314/APJCP.2013.14.5.2717
- Trial Watch vol.2, pp.9, 2013, https://doi.org/10.4161/onci.25595
- High expression of Toll-like receptor 5 correlates with better prognosis in non-small-cell lung cancer: an anti-tumor effect of TLR5 signaling in non-small cell lung cancer vol.140, pp.4, 2014, https://doi.org/10.1007/s00432-014-1616-4
- Evaluation of the Radiation Pneumonia Development Risk in Lung Cancer Cases vol.15, pp.17, 2014, https://doi.org/10.7314/APJCP.2014.15.17.7371
- Plant Extracts and Plant-Derived Compounds: Promising Players in Countermeasure Strategy Against Radiological Exposure: A Review vol.15, pp.6, 2014, https://doi.org/10.7314/APJCP.2014.15.6.2405
- Strahlenschutz von Normalgewebszellen vol.190, pp.8, 2014, https://doi.org/10.1007/s00066-014-0637-x
- Trial Watch: Radioimmunotherapy for oncological indications vol.3, pp.9, 2014, https://doi.org/10.4161/21624011.2014.954929
- Establishment of a mouse model of 70% lethal dose by total-body irradiation vol.32, pp.2, 2016, https://doi.org/10.5625/lar.2016.32.2.116
- Modeling DNA damage-induced pneumopathy in mice: insight from danger signaling cascades vol.12, pp.1, 2017, https://doi.org/10.1186/s13014-017-0865-1
- Mitigation of Radiation-Induced Epithelial Damage by the TLR5 Agonist Entolimod in a Mouse Model of Fractionated Head and Neck Irradiation vol.187, pp.5, 2017, https://doi.org/10.1667/RR14514.1
- Toll-like receptor 5 agonist CBLB502 induces radioprotective effects in vitro vol.49, pp.6, 2017, https://doi.org/10.1093/abbs/gmx034
- Radioprotective agents for radiation therapy: future trends vol.10, pp.15, 2014, https://doi.org/10.2217/fon.14.175
- Repeated injection of KMRC011, a medical countermeasure for radiation, can cause adverse health effects in cynomolgus monkeys pp.0260437X, 2018, https://doi.org/10.1002/jat.3719
- Radioprotective Efficiency of Recombinant Flagellin and Interleukin-1 Beta with Combined Administration vol.52, pp.10, 2019, https://doi.org/10.1007/s11094-019-1910-1